Natera Partners With Angiex For CtDNA Monitoring In Solid Tumor Trial Using Signatera
(RTTNews) - Natera, Inc. (NTRA), a clinical genetic testing company announced on Thursday that it will collaborate with privately held Angiex, Inc., to use its Signatera test for circulating tumor DNA monitoring in a Phase I study of AGX101, an investigational nuclear-delivered a
(RTTNews) - Natera, Inc. (NTRA), a clinical genetic testing company announced on Thursday that it will collaborate with privately held Angiex, Inc., to use its Signatera test for circulating tumor DNA monitoring in a Phase I study of AGX101, an investigational nuclear-delivered a
BELLINGS Intelligence Score: 8
Why it matters
This is a routine collaboration announcement in the biotech/clinical testing sector with no direct impact on credit markets, underwriting, or regulatory frameworks relevant to sophisticated credit professionals.
Sources
Nasdaq
Natera Partners With Angiex For CtDNA Monitoring In Solid Tumor Trial Using Signatera
(RTTNews) - Natera, Inc. (NTRA), a clinical genetic testing company announced on Thursday that it will collaborate with privately held Angiex, Inc., to use its Signatera test for circulating tumor DNA monitoring in a Phase I study of AGX101, an investigational nuclear-delivered a